# A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.

> **NCT05421078** · PHASE2 · COMPLETED · sponsor: **NewAmsterdam Pharma** · enrollment: 102 (actual)

## Conditions studied

- Dyslipidemia
- Hypercholesterolemia
- High Cholesterol

## Interventions

- **DRUG:** Obicetrapib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05421078
- **Lead sponsor:** NewAmsterdam Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-27
- **Primary completion:** 2023-03-24
- **Final completion:** 2023-04-21
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05421078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05421078, "A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05421078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*